Myelodysplastic Syndromes: Advances and Challenges in Pathophysiology and Therapeutic Approaches
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: 31 July 2024 | Viewed by 107
Special Issue Editor
Special Issue Information
Dear Colleagues,
Myelodysplastic syndromes (MDS) are a group of heterogeneous myeloid clonal diseases originating from hematopoietic stem cells, characterized by abnormal differentiation and development of myeloid cells, manifested as ineffective hematopoiesis, refractory cytopenia, hematopoietic failure, and a high risk of transformation to acute myeloid leukemia (AML). Since the etiology and pathogenesis have not been fully elucidated, there is no unified, specific treatment plan for MDS. Chemotherapy, immunotherapy, thalidomide and its analogues, and hematopoietic stem cell transplantation are the most researched treatments for MDS. In this Special Issue, we highlight recent advances in our understanding of the pathophysiology of MDS and new therapeutic approaches, and we welcome submissions of original research papers and review papers.
Dr. Maria Cuzzola
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- myelodysplastic syndrome
- molecular pathology
- immunotherapy
- thalidomide and its analogues
- hematopoietic stem cell transplantation
